Actuate’s Ewing Sarcoma Trial Shows Promise in Pediatric Sarcomas
Actuate Therapeutics has completed Phase 1 of its elraglusib study in pediatric patients with refractory cancers, observing promising results...
Lisata and WarpNine Announce ILSTA Trial Completion & Data
Lisata Therapeutics and WARPNINE Incorporated completed patient enrollment in their Phase 1b/2a iLSTA trial in Australia. The trial evaluates...
Keros Doses First Patient in Phase 3 Trial of Elritercept
Keros Therapeutics initiated Phase 3 trials for elritercept, a treatment for transfusion-dependent anemia in patients with myelodysplastic syndromes (MDS)....
Gets FDA Orphan Drug Designation for AML Treatment
ImCheck Therapeutics’ lead candidate, ICT01, has received FDA Orphan Drug Designation for the treatment of acute myeloid leukemia (AML)....
Strong Clinical Trial Results for Urcosimod
OKYO Pharma’s Phase 2 trial of urcosimod for neuropathic corneal pain (NCP) yielded positive top-line results. The trial involved...
CUE-101 & Pembro Show Promising 50% Response in HPV+ Head & Neck Cancer Trial
Cue Biopharma announced positive clinical updates for CUE-101, its lead drug candidate for recurrent/metastatic head and neck squamous cell...
Zervimesine Shows Promise in Dementia with Lewy Bodies
Cognition Therapeutics announced positive Phase 2 results for zervimesine in treating dementia with Lewy bodies (DLB) at the Alzheimer’s...
Voyager Adds Fourth Alzheimer’s Program to Pipeline
Voyager Therapeutics has expanded its Alzheimer’s disease pipeline with a new gene therapy program targeting APOE, the strongest genetic...
Sellas’ SLS009 Shows Promise in AML Phase 2 Trial, FDA Guides First-Line Study
SELLAS Life Sciences‘ Phase 2 trial of SLS009 (tambiciclib), a CDK9 inhibitor, for relapsed/refractory acute myeloid leukemia (r/r AML)...
Positive Phase 3 Obesity Trial Results for HRS9531 in China
Hengrui Pharma and Kailera Therapeutics announced positive topline data from a Phase 3 clinical trial of HRS9531/KAI-9531, a novel...